Structured evidence table for Glucosamine Joint Mobility Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Glucosamine Joint Mobility Randomized Trial | Temporomandibular disorders (TMDs) encompass a spectrum of musculoskeletal and joint conditions of the masticatory system that frequently lead to chronic pain, limited function, and reduced quality of life. | 3 | Gazali M (2026) | Diagnosis-based pathways for conservative and minimally invasive management of temporomandibular disorders: a scoping review. |
| Glucosamine Joint Mobility Randomized Trial | Although conservative and minimally invasive approaches are recommended as first-line therapies, their comparative efficacy remains unclear.This scoping review mapped evidence from randomized controlled trials (RCTs) published between 2015 and 2025 to identify diagnosis-based effective management pathways for TMDs. | 3 | Gazali M (2026) | Diagnosis-based pathways for conservative and minimally invasive management of temporomandibular disorders: a scoping review. |
| Glucosamine Joint Mobility Randomized Trial | Overall, the evidence from the past decade supports a diagnosis-driven, stepwise model that emphasizes conservative multimodal care as the cornerstone of TMD management. | 3 | Gazali M (2026) | Diagnosis-based pathways for conservative and minimally invasive management of temporomandibular disorders: a scoping review. |
| Glucosamine Joint Mobility Randomized Trial | It causes chronic pain, reduced mobility, and disability, affecting 607 million individuals worldwide, with nearly 46.6 million new cases annually []. | 4 | Muacevic Alexander (2026) | Evidence-Based Use of Undenatured Type II Collagen in the Management of Osteoarthritis in the Indian Subcontinent and Southeast Asia: A Narrative Review and an Expert Opinion |
| Glucosamine Joint Mobility Randomized Trial | 11 12 13 14 15 11 15 HLA-DRB1 HLA-DQB1 Genetic polymorphisms in sterol regulatory element-binding protein 2 (rs2228314) [], interleukin-6 (rs1800795) [], and resistin (RETN) [] in Indian and Pakistani cohorts and growth differentiation factor 5 (rs143383) [],, andin Thai populations [] are linked to OA risk. | 4 | Muacevic Alexander (2026) | Evidence-Based Use of Undenatured Type II Collagen in the Management of Osteoarthritis in the Indian Subcontinent and Southeast Asia: A Narrative Review and an Expert Opinion |
| Glucosamine Joint Mobility Randomized Trial | Need for expert opinion Despite growing clinical and mechanistic evidence for collagen supplementation in OA, several gaps and challenges remain in translating this knowledge into clinical practice, especially in the Indian subcontinent and Southeast Asia. | 4 | Muacevic Alexander (2026) | Evidence-Based Use of Undenatured Type II Collagen in the Management of Osteoarthritis in the Indian Subcontinent and Southeast Asia: A Narrative Review and an Expert Opinion |
| Glucosamine Joint Mobility Randomized Trial | 1 2 3 4 6 7 8 9 10 1 Osteoarthritis (OA) is the most prevalent degenerative joint disease globally and the second most common rheumatologic condition []. | 4 | Muacevic Alexander (2026) | Evidence-Based Use of Undenatured Type II Collagen in the Management of Osteoarthritis in the Indian Subcontinent and Southeast Asia: A Narrative Review and an Expert Opinion |
Source documents